Nath Bio-Genes FY26 Results: ₹42 Cr Profit, ₹445 Cr Revenue

Nath Bio-Genes (India) Ltd has reported its financial results for the fiscal year ending March 31, 2026. The company posted a standalone profit after tax of ₹42.14 crore on revenue of ₹431.60 crore. On a consolidated basis, revenue reached ₹445.10 crore, with profit after tax at ₹38.60 crore.

Key Financials and Corporate Actions

The board of directors has recommended a final dividend of ₹2 per equity share for the fiscal year 2025-26. This recommendation is subject to shareholder approval at the upcoming annual general meeting.

In significant corporate governance moves, the board also proposed the reappointment of Mr. Hitesh Rajnikant Purohit as an Independent Director for a five-year term starting March 30, 2027. Additionally, a substantial increase in the Managing Director's annual remuneration was proposed.

Significance for Investors

The proposed dividend offers a direct return to shareholders, often seen as a signal of the company's financial health and confidence.

The proposed hike in the Managing Director's remuneration, from ₹66 lakh annually to ₹144 lakh, requires careful shareholder consideration regarding its justification and alignment with company performance.

Investors will also be closely watching the resolution of an auditor's note flagging potential recovery issues concerning advances made to farmers, totaling ₹600.73 lakh.

Company Background

Nath Bio-Genes is a well-established player in India's agri-tech industry, boasting over four decades of experience in developing and marketing hybrid seeds. The company has a consistent track record of rewarding its shareholders, having also recommended a ₹2 per share dividend for the previous fiscal year (FY24-25).

Shareholder Decisions Ahead

Shareholders are set to vote on several key proposals:

• The final dividend of ₹2 per equity share for FY25-26.
• The revised annual remuneration for the Managing Director, set to increase to ₹1.44 crore from ₹66 lakh, effective January 1, 2026.
• The reappointment of Mr. Hitesh Rajnikant Purohit as an Independent Director for another five-year term, commencing March 30, 2027.

Auditor's Note on Advances

A specific point of attention is Note 31.1 in the auditor's report. It highlights the potential non-recovery of ₹600.73 lakh against advances previously granted to farmers or growers. This issue has been a recurring point in past financial reports.

Competitive Landscape

Nath Bio-Genes operates within a competitive agricultural technology sector, facing rivals such as Kaveri Seed Co., JK Agri Genetics, and Godrej Agrovet.

What to Monitor Next

Investors and analysts will be tracking:

• The outcomes of the shareholder voting on the dividend and MD remuneration increase.
• Any developments regarding the recovery of the farmer advances highlighted by the auditor.
• Future quarterly and annual financial performance reports.
• Updates on the company's research and development pipeline or new product launches.